Bispecific antibody · Immune activation, directed at CD19 and CD3 (CD3E) · developed by Cullinan Therapeutics
CLN-978 is a T-cell engaging bispecific antibody that binds CD19 on target cells and CD3 on T-cells, cross-linking the two to induce a cytotoxic T-lymphocyte response against CD19-expressing cells. An albumin-binding domain extends its half-life. It is being studied in Sjögren's syndrome.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07041099 | Phase 1 | Sjögren | Recruiting | CGEM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
SjögrenSjogren DiseaseSjogren's Syndrome
Updated Nov 8, 2026. Something wrong or missing? Report it on the CGEM page.
See CGEM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CGEM catalysts and pipeline →